Pande: Biotech market shifting to value reproducible platforms over individual assets
Vijay Pande · Pande & Conde: When (and How) Biology Becomes Engineering · Mar 23, 2018 · at 10:41
Vijay Pande, General Partner at Andreessen Horowitz (a16z), explains how market perception of biotech platform technology is evolving relative to traditional single-asset drug models.
0:00 / 0:22exact quote · 22.8s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“That's a good point. Like, ML is a platform, ah, amongst others, and then there's data generating platforms, there's data analysis platforms, and that, that platform, I think, really could be a really interesting shift, and we're seeing more and more companies that way that are, ah, you know, before it used to be that the platform was never really valued very much, it's all about the assets. And now we're getting to the point where people are very curious if platforms can reproducibly create multiple assets.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Vijay Pande
Pande: Cancer could easily not exist in 10 years
“Cancer could easily just not exist in 10 years, and that's due to this change in how we think about things, and there's all these things on the back end.”
Vijay Pande: Compute costs will fall a million-fold over 20 years
“The nice thing about the exponentials is that, you know, things will go down a factor of a thousand, like, every 10 years on the Moore's Law side, and we'll continue to see that. So, a thousand, maybe in 20 years, a million, you know, a thousand times a thousa…”
Pande: Healthcare AI needs a 10x improvement threshold to overcome stigma
“Yeah, so I think the bar is different. This might be the magic has to get to 10 X. Mm-hmm. Something where 10% is probably within noise and without doubt or something like that, but 10 X is kind of the thing where, like, okay, okay. We have to think of things …”
Pande: Healthcare service providers will eventually transition into AI companies
“Well, you can imagine a services company that's providing some sort of healthcare service. It's training AI with its workers. And then the easy things, which are probably the boring things anyways, AI starts to do. And then the more interesting, complicated th…”
Pande: FDA rejects new drugs that are cheaper but equal in efficacy
“If you had a drug that was as good as the best drug, but cheaper, That still can't get that won't go by the FDA because they actually has to be better than the last drug, even if it's not better scientifically, but it's better in other ways.”